Mette Skalshøi Kjær

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 413 citations · Full text

Placebo-controlled Phase 2, Hepatology, Liver Physiology +6

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Philip N. Newsome, Iris Kliers, Laura Østergaard et al. · New England Journal of Medicine · 2025 · 398 citations

Alcohol drinking pattern and risk of alcoholic liver cirrhosis: A prospective cohort study

Gro Askgaard, Morten Grønbæk, Mette Skalshøi Kjær et al. · Journal of Hepatology · 2015 · 243 citations

Alcohol Drinking Pattern, Substance Abuse, Substance Use +14

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Naim Alkhouri, Robert Herring, Heidi Kabler et al. · Journal of Hepatology · 2022 · 193 citations

Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study

Quentin M. Anstee, Tina Landsvig Berentzen, Louise Maymann Nitze et al. · The Lancet Regional Health - Europe · 2023 · 94 citations · Full text